RecruitingPhase 3NCT06961968
Randomized Withdrawal Study in Patients With Schizophrenia
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
Sponsor
Vanda Pharmaceuticals
Enrollment
400 participants
Start Date
May 14, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- Males or females 18 to 65 years of age (inclusive)
- Diagnosed with schizophrenia per DSM-5 criteria
- In need of ongoing psychiatric treatment
Exclusion Criteria1
- DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months
Interventions
DRUGiloperidone
iloperidone LAI
DRUGplacebo
matching placebo
Locations(22)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06961968
Related Trials
Tolerability of MDMA in Schizophrenia
NCT057703751 location
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT0688278555 locations
Cerebellar Modulation of Cognition in Psychosis
NCT061077642 locations
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
NCT037940761 location
Cerebellar Stimulation and Cognitive Control
NCT032171101 location